These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31589081)

  • 21. The humanistic and economic burden of systemic lupus erythematosus : a systematic review.
    Meacock R; Dale N; Harrison MJ
    Pharmacoeconomics; 2013 Jan; 31(1):49-61. PubMed ID: 23329592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.
    Garris C; Jhingran P; Bass D; Engel-Nitz NM; Riedel A; Dennis G
    J Med Econ; 2013; 16(5):667-77. PubMed ID: 23425294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The economic burden of systemic lupus erythematosus in commercially- and medicaid-insured populations in the United States.
    Clarke AE; Yazdany J; Kabadi SM; Durden E; Winer I; Griffing K; Costenbader KH
    Semin Arthritis Rheum; 2020 Aug; 50(4):759-768. PubMed ID: 32531505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs.
    Anandarajah AP; Luc M; Ritchlin CT
    Lupus; 2017 Jun; 26(7):756-761. PubMed ID: 27831537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden.
    Reese T; Dickson AL; Shuey MM; Gandelman JS; Barnado A; Barker KA; Neal JE; Khan OA; Dupont WD; Stein CM; Chung CP
    Lupus; 2019 Jul; 28(8):954-960. PubMed ID: 31221051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of disease and real-world treatment patterns of patients with systemic lupus erythematosus in the Australian OPAL dataset.
    Ciciriello S; Littlejohn G; O'Sullivan C; Smith T; Deakin CT
    Clin Rheumatol; 2023 Nov; 42(11):2971-2980. PubMed ID: 37407907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
    Feldman CH; Yazdany J; Guan H; Solomon DH; Costenbader KH
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1712-21. PubMed ID: 26097166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.
    Chang JC; Costenbader KH
    Semin Arthritis Rheum; 2022 Oct; 56():152042. PubMed ID: 35738041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: A retrospective, observational study.
    Tanaka Y; Mizukami A; Kobayashi A; Ito C; Matsuki T
    Int J Rheum Dis; 2018 Aug; 21(8):1609-1618. PubMed ID: 30146745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth With Systemic Lupus Erythematosus.
    Chang JC; Davis AM; Klein-Gitelman MS; Cidav Z; Mandell DS; Knight AM
    Arthritis Care Res (Hoboken); 2021 Jan; 73(1):30-38. PubMed ID: 32937032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Healthcare Utilization and Costs of Systemic Lupus Erythematosus by Disease Severity in the United States.
    Murimi-Worstell IB; Lin DH; Kan H; Tierce J; Wang X; Nab H; Desta B; Alexander GC; Hammond ER
    J Rheumatol; 2021 Mar; 48(3):385-393. PubMed ID: 32611669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients: a Taiwan nationwide population-based study.
    Chiu YM; Chuang MT; Lang HC
    Rheumatol Int; 2016 Nov; 36(11):1507-1514. PubMed ID: 27534653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus.
    Shah M; Chaudhari S; McLaughlin TP; Kan HJ; Bechtel B; Dennis GJ; Molta CT
    Clin Ther; 2013 Apr; 35(4):486-97. PubMed ID: 23587268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Socioeconomic status at diagnosis influences the incremental direct medical costs of systemic lupus erythematosus: A longitudinal population-based study.
    McCormick N; Marra CA; Sadatsafavi M; Aviña-Zubieta JA
    Semin Arthritis Rheum; 2020 Feb; 50(1):77-83. PubMed ID: 31358362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel.
    Petri M; Bechtel B; Dennis G; Shah M; McLaughlin T; Kan H; Molta C
    Lupus; 2014 Sep; 23(10):1006-13. PubMed ID: 24786783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany.
    Schultze M; Garal-Pantaler E; Pignot M; Levy RA; Carnarius H; Schneider M; Gairy K
    BMC Rheumatol; 2024 May; 8(1):18. PubMed ID: 38755673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population.
    Li T; Carls GS; Panopalis P; Wang S; Gibson TB; Goetzel RZ
    Arthritis Rheum; 2009 Jun; 61(6):755-63. PubMed ID: 19479688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.